Scott Gottlieb, who served as commissioner of the Food and Drug Administration (FDA) during President-elect Trump’s first ...

Scott Gottlieb, who served early on in Trump's first term, is now warning senators about the impact Kennedy could have on ...

Trump administration pick for Health and Human Services department could cause rise in preventable disease, health expert ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

The past couple of years have been terrific for stocks, with the benchmark S&P 500 index up a whopping 57.1% since the end of ...

A growth path that is overly dependent on a few oligarchs may not answer the needs of a large and complex democracy ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Despite Pfizer 's ( PFE 1.47%) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...